RxDoctor Payments DataLook up a doctor →

Tara Iyengar, MD

Hematology & Oncology · Scottsdale, AZNPI 1922217660

Payments from drug & device makers

$1,503,489in general payments, 2019–2025

Across 545 payments — averaging $2758.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1.5M
  • Novartis$1K
  • AstraZeneca$697
  • Merck$647
  • Johnson & Johnson$543
  • Genentech USA, Inc.$539
  • plus $7K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer88$1,492,824
Novartis40$1,420
AstraZeneca(2 entities)29$697
Merck30$647
Johnson & Johnson(2 entities)29$543
Genentech USA, Inc.24$539
AbbVie23$440
E.r. Squibb & Sons, L.L.C.24$431
Amgen16$397
Sanofi17$377
Lilly USA, LLC13$302
Incyte Corporation13$262
Takeda Pharmaceuticals U.S.A., Inc.11$242
Daiichi Sankyo Inc.9$242
Stemline Therapeutics Inc.5$233
Astellas Pharma US Inc12$227
GSK11$208
Gilead9$186
Bristol Myers Squibb9$185
Array Biopharma Inc10$181
Pharmacyclics LLC, An Abbvie Company8$157
Sobi, Inc2$145
AVEO Pharmaceuticals, Inc.7$141
Jazz Pharmaceuticals Inc.5$131
Boehringer Ingelheim6$123
Karyopharm Therapeutics Inc.5$123
Eisai Inc.5$122
Regeneron Healthcare Solutions, Inc.5$114
Genmab U.S., Inc.4$111
Bayer6$109
Tersera Therapeutics LLC3$105
Seagen Inc.6$95
Sumitomo Pharma America, Inc.2$85
Taiho Oncology, Inc.4$84
CTI Biopharma Corp.3$76
Mirati Therapeutics, Inc.3$75
Blueprint Medicines Corporation3$72
Lexicon Pharmaceuticals, Inc.1$71
Ipsen Biopharmaceuticals, Inc3$69
Puma Biotechnology, Inc.3$65
Rigel Pharmaceuticals, Inc.4$59
Adaptive Biotechnologies Corporation2$48
EMD Serono, Inc.3$47
Deciphera Pharmaceuticals Inc.2$47
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)1$46
Servier Pharmaceuticals LLC2$46
ADC Therapeutics America, Inc.2$46
Beigene USA, Inc.2$43
GE HealthCare1$31
Syndax Pharmaceuticals, Inc.1$28
Iovance Biotherapeutics, Inc.1$28
Acrotech Biopharma Inc.1$26
Epizyme, Inc.1$26
EUSA Pharma (US) LLC1$25
Caris MPI, Inc.1$24
Kyowa Kirin, Inc.1$24
Dendreon Pharmaceuticals LLC1$24
Exelixis Inc.1$23
Springworks Therapeutics, Inc.1$22
Sun Pharmaceutical Industries Inc.1$21

How this compares

$1,503,489 in reported general payments places this provider in the 85th percentile of 261 hematology & oncology providers in Arizona.

See all hematology & oncology providers in Arizona →

Medicare billing

Part B allowed, 2024
$2,309,137
Medicare patients
618
Services billed
123,263

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Scottsdale

See the full list for Arizona →

Where these figures come from

Is this you, or does something look wrong? →